Castleman disease


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia, Wikipedia.

Castleman disease

 [kas´el-man]
a benign or premalignant condition resembling lymphoma but without recognizable malignant cells; there are isolated masses of lymphoid tissue and lymph node hyperplasia, usually in the abdominal or mediastinal area.

be·nign giant lymph node hy·per·pla·si·a

solitary masses of lymphoid tissue containing concentric perivascular aggregates of lymphocytes, occurring usually in the mediastinum or hilar region of young adults; similar changes have been reported outside the mediastinum and, if associated with interfollicular sheets of plasma cells, may progress to lymphoma or plasmacytoma.

Castleman disease

(kas′l-măn)
[Benjamin Castleman, U.S. pathologist, 1906–1982]
An occasionally aggressive illness marked by excessive growth of lymphoid tissue either localized in a single lymph node group or in multiple regions of the body. Although the cause is not precisely known, its associations with acquired immunodeficiency syndrome, Kaposi's sarcoma, and human herpes virus 8 infection have led some experts to propose that it has an infectious basis. Localized disease responds well to surgical resection. Widespread disease can sometimes be treated effectively with chemotherapy.

Castleman,

Benjamin, U.S. pathologist, 1906-1982.
Castleman disease - solitary masses of lymphoid tissue containing concentric perivascular aggregates of lymphocytes. Synonym(s): benign giant lymph node hyperplasia; Castleman tumor
Castleman tumor - Synonym(s): Castleman disease
References in periodicals archive ?
Chaloupka JC, Castillo M, Hudgins E Castleman disease in the neck: Atypical appearance on CT.
Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease.
Primary infusion lymphoma has been reported with both Kaposi sarcoma and multicentric Castleman disease in patients with HIV.
Castleman disease (angiofollicular lymphoid hyperplasia) is a rare disorder that was first described in 1952 as a localized mediastinal lymph node hyperplasia resembling thymoma.
Small vessel proliferation and hyalinization in the interfollicular areas and within angiofollicular structures in adjacent portal areas may be a prominent finding, which may mimic the hyaline-vascular type of Castleman disease.
Hyalinevascular Castleman disease sometimes demonstrates proliferating and dysplastic FDCs, and a number of cases of FDC sarcomas complicating Castleman disease have been reported, which suggests a hyperplasia-dysplasia-neoplasia sequence of FDC sarcoma in some cases.
The nine new antineoplastic agents and their indications are belinostat (Beleodaq) for peripheral T-cell lymphoma; blinatumomab (Blincyto) for acute lymphoblastic leukemia; ceritinib (Zykadia) for non-small cell lung cancer; idelalisib (Zydelig) for some types of leukemia and lymphoma; nivolumab (Opdivo) for metastatic melanoma; olaparib (Lynparza) for ovarian cancer; pembrolizumab (Keytruda) for unresectable or metastatic melanoma; ramucirumab (Cyramza) for gastric or gastroesophageal adenocarcinoma and metastatic non-small cell lung cancer; and siltuximab (Sylvant) for multicentric Castleman disease.
High incidence of Kaposi sarcoma associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease.
Castleman Disease in the 21st Century: An Update on Diagnosis, Assessment, and Therapy.
HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma.